Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
Immunometabolic Effects of Time Restricted Eating in Non-alcoholic Fatty Liver Disease
1 other identifier
interventional
60
1 country
1
Brief Summary
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2023
CompletedFirst Submitted
Initial submission to the registry
June 26, 2023
CompletedFirst Posted
Study publicly available on registry
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2024
CompletedAugust 1, 2023
July 1, 2023
1 year
June 26, 2023
July 26, 2023
Conditions
Outcome Measures
Primary Outcomes (4)
Change in plasma inflammatory response to a high-fat meal: C-reactive protein (CRP)
Postprandial changes in CRP (mg/L) will be measured in response to a high-fat meal
To be assessed at baseline and post 8-week intervention
Change in plasma inflammatory response to a high-fat meal: Interleukin-6 (IL-6)
Postprandial changes in IL-6 (pg/mL) will be measured in response to a high-fat meal
To be assessed at baseline and post 8-week intervention
Change in plasma inflammatory response to a high-fat meal: Interleukin-1-beta (IL-1β)
Postprandial changes in IL-1β (pg/mL) will be measured in response to a high-fat meal
To be assessed at baseline and post 8-week intervention
Change in plasma inflammatory response to a high-fat meal: Tumor necrosis factor alpha (TNF-α)
Postprandial changes in (TNF-α) (pg/mL) will be measured in response to a high-fat meal
To be assessed at baseline and post 8-week intervention
Secondary Outcomes (20)
Change in metabolic response to a high-fat meal: Glucose
To be assessed at baseline and post 8-week intervention
Change in metabolic response to a high-fat meal: Insulin
To be assessed at baseline and post 8-week intervention
Change in metabolic response to a high-fat meal: Glucagon
To be assessed at baseline and post 8-week intervention
Change in metabolic response to a high-fat meal: Triglycerides
To be assessed at baseline and post 8-week intervention
Change in metabolic response to a high-fat meal: Non-esterified fatty acids (NEFA)
To be assessed at baseline and post 8-week intervention
- +15 more secondary outcomes
Study Arms (2)
Standard healthy eating advice
ACTIVE COMPARATORSubjects in this group will be counselled according to the Irish National Healthy Eating Guidelines.
eTRE plus Mediterranean diet
EXPERIMENTALSubjects in this group will be asked to restrict their eating to 8-hours daily (8am - 4pm) and to adhere to a Mediterranean style diet.
Interventions
Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
Eligibility Criteria
You may qualify if:
- Males and females
- Age 18-65 years, from all ethnic groups, capable of providing informed consent to participate
- Obesity (body mass index \>30kg/m\^2) and of stable body weight (±3% for ≥3 months)
- Fasting blood glucose \<7.0 mmol/L and HbA1c \<6.5%.
- Liver fat \>10% (CAP score \>238 dB/m) and no fibrosis (liver stiffness score 2-7 kPa) as assessed by liver elastography (FibroScan)
You may not qualify if:
- Impaired renal function
- Abnormal hematocrit
- History of cardiovascular events
- Uncontrolled hypertension
- Type 2 diabetes
- Medications or supplements known to affect glucose or lipid metabolism
- Active inflammatory, autoimmune, infectious, gastrointestinal, or malignant disease
- Uncontrolled neurological or psychiatric disease
- Iron deficiency anemia, (hemoglobin \< 12g/dl men, \< 11g/dl women)
- Fatty acid supplements and consumers of high doses of anti- antioxidant vitamins (A, C, E, b-carotene)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University College Dublinlead
- St. James's Hospital, Irelandcollaborator
Study Sites (1)
University College Dublin
Dublin, Leinster, D04 V1W8, Ireland
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 26, 2023
First Posted
August 1, 2023
Study Start
June 1, 2023
Primary Completion
June 1, 2024
Study Completion
July 1, 2024
Last Updated
August 1, 2023
Record last verified: 2023-07